Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting.

Nakagawa R, Ohnishi T, Kobayashi H, Yamaoka T, Yajima T, Tanimura A, Kato T, Yoshizawa K.

Neuropsychiatr Dis Treat. 2017 Apr 19;13:1115-1124. doi: 10.2147/NDT.S133145. eCollection 2017.

2.

The role of cognitive activity in cognition protection: from Bedside to Bench.

Li BY, Wang Y, Tang HD, Chen SD.

Transl Neurodegener. 2017 Mar 28;6:7. doi: 10.1186/s40035-017-0078-4. eCollection 2017. Review.

3.

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.

Blanco-Silvente L, Castells X, Saez M, Barceló MA, Garre-Olmo J, Vilalta-Franch J, Capellà D.

Int J Neuropsychopharmacol. 2017 Feb 13. doi: 10.1093/ijnp/pyx012. [Epub ahead of print]

4.
5.

Informal Care Time and Cost in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Change Observed.

Lacey L, Bobula J, Niecko T, Leibman C.

Neurol Ther. 2017 Jun;6(1):11-23. doi: 10.1007/s40120-016-0056-2. Epub 2016 Nov 22.

6.
7.

A Two-Year Treatment of Amnestic Mild Cognitive Impairment using a Compound Chinese Medicine: A Placebo Controlled Randomized Trail.

Zhang J, Liu Z, Zhang H, Yang C, Li H, Li X, Chen K, Zhang Z.

Sci Rep. 2016 Jul 4;6:28982. doi: 10.1038/srep28982.

8.

Outcome measures for Parkinson's disease dementia: a systematic review.

Holden SK, Jones WE, Baker KA, Boersma IM, Kluger BM.

Mov Disord Clin Pract. 2016 Jan-Feb;3(1):9-18. Epub 2015 Sep 16.

9.

Donepezil Adherence, Persistence and Time to First Discontinuation in a Three-Year Follow-Up of Older People.

Ndukwe HC, Nishtala PS.

Dement Geriatr Cogn Dis Extra. 2015 Dec 11;5(3):482-91. doi: 10.1159/000441894. eCollection 2015 Sep-Dec.

10.

Drug Therapy for Behavioral and Psychological Symptoms of Dementia.

Wang F, Feng TY, Yang S, Preter M, Zhou JN, Wang XP.

Curr Neuropharmacol. 2016;14(4):307-13. Review.

11.

Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulation.

Fang J, Wu P, Yang R, Gao L, Li C, Wang D, Wu S, Liu AL, Du GH.

Acta Pharm Sin B. 2014 Dec;4(6):430-7. doi: 10.1016/j.apsb.2014.10.002. Epub 2014 Nov 22.

12.

PET Radioligands for Imaging of Tau Pathology: Current Status.

Choe YS, Lee KH.

Nucl Med Mol Imaging. 2015 Dec;49(4):251-7. doi: 10.1007/s13139-015-0374-9. Epub 2015 Oct 2. Review.

13.

Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study.

Rutherford G, Lithgow B, Moussavi Z.

J Exp Neurosci. 2015 Jun 3;9:43-51. doi: 10.4137/JEN.S24004. eCollection 2015.

14.

Preventive role of Indian black pepper in animal models of Alzheimer's disease.

Subedee L, Suresh RN, Mk J, Hl K, Am S, Vh P.

J Clin Diagn Res. 2015 Apr;9(4):FF01-4. doi: 10.7860/JCDR/2015/8953.5767. Epub 2015 Apr 1.

15.

Neurocognitive challenges in brain tumor survivors: is there anything we can do?

Kleinberg L.

J Clin Oncol. 2015 May 20;33(15):1633-6. doi: 10.1200/JCO.2014.60.2805. Epub 2015 Apr 20. No abstract available.

16.

Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression.

Huntley JD, Gould RL, Liu K, Smith M, Howard RJ.

BMJ Open. 2015 Apr 2;5(4):e005247. doi: 10.1136/bmjopen-2014-005247. Review. Erratum in: BMJ Open. 2017 Aug 30;7(8):e005247corr1.

17.

Donepezil treatment in ethnically diverse patients with Alzheimer disease.

Tinklenberg JR, Kraemer HC, Yaffe K, O'Hara R, Ringman JM, Ashford JW, Yesavage JA, Taylor JL; California Alzheimer's Disease Centers.

Am J Geriatr Psychiatry. 2015 Apr;23(4):384-90. doi: 10.1016/j.jagp.2014.09.007. Epub 2014 Sep 28.

18.

Assessment and management of behavioral and psychological symptoms of dementia.

Kales HC, Gitlin LN, Lyketsos CG.

BMJ. 2015 Mar 2;350:h369. doi: 10.1136/bmj.h369. Review.

19.

Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors.

Maxwell CJ, Stock K, Seitz D, Herrmann N.

Can J Psychiatry. 2014 Dec;59(12):624-31. Review.

20.

Supplemental Content

Support Center